BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 7260907)

  • 1. Synergistic effects with inhibitors of de novo pyrimidine synthesis, acivicin, and N-(phosphonacetyl)-L-aspartic acid.
    Loh E; Kufe DW
    Cancer Res; 1981 Sep; 41(9 Pt 1):3419-23. PubMed ID: 7260907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of acivicin and PALA, singly and in combination, on de novo pyrimidine biosynthesis.
    Kensler TW; Jayaram HN; Cooney DA
    Adv Enzyme Regul; 1982; 20():57-73. PubMed ID: 7113804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective inhibition of pyrimidine synthesis and depletion of nucleotide pools by N-(phosphonacetyl)-L-aspartate.
    Moyer JD; Handschumacher RE
    Cancer Res; 1979 Aug; 39(8):3089-94. PubMed ID: 455293
    [No Abstract]   [Full Text] [Related]  

  • 4. Kinetics of N-(phosphonacetyl)-L-aspartate and pyrazofurin depletion of pyrimidine ribonucleotide and deoxyribonucleotide pools and their relationship to nucleic acid synthesis in intact and permeabilized cells.
    Moyer JD; Smith PA; Levy EJ; Handschumacher RE
    Cancer Res; 1982 Nov; 42(11):4525-31. PubMed ID: 7127293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Collateral sensitivity to N-(phosphonacetyl)-L-aspartic acid in a line of P388 leukemia cells selected for resistance to L-(alpha S, 5S)-alpha-amino-3- chloro-4,5-dihydro-5-isoxazoleacetic acid (acivicin).
    Ardalan B; Jayaram HN; Johnson RK
    Cancer Res; 1983 Apr; 43(4):1598-601. PubMed ID: 6831405
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antipyrimidine effects of five different pyrimidine de novo synthesis inhibitors in three head and neck cancer cell lines.
    Peters GJ
    Nucleosides Nucleotides Nucleic Acids; 2018; 37(6):329-339. PubMed ID: 29723133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pyrimidine nucleosides enhance the efficacy of inhibitors of pyrimidine biosynthesis in cultured hepatocellular carcinoma cells.
    Jacobsen LB; Putnam JE; Sawick DP; Cassady JM; Morré DJ
    Life Sci; 1988; 42(8):913-8. PubMed ID: 3343891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic effects of acivicin and N-(phosphonacetyl)-L-aspartic acid in a biochemically designed trial against a N-(phosphonacetyl)-L-aspartic acid-resistant variant of the Lewis lung carcinoma.
    Kensler TW; Reck LJ; Cooney DA
    Cancer Res; 1981 Mar; 41(3):905-9. PubMed ID: 7459876
    [No Abstract]   [Full Text] [Related]  

  • 9. Flux through the de novo pyrimidine pathway in vivo. Effect of N-phosphonacetyl-L-aspartate, a potent inhibitor of aspartate transcarbamylase.
    Monks A; Anderson LW; Strong J; Cysyk RL
    J Biol Chem; 1983 Nov; 258(22):13564-9. PubMed ID: 6417130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of inhibitors of the de novo pyrimidine biosynthetic pathway on serum uridine levels in mice.
    Karle JM; Anderson LW; Dietrick DD; Cysyk RL
    Cancer Res; 1981 Dec; 41(12 Pt 1):4952-5. PubMed ID: 6171344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancement of antitumor activity of glutamine antagonists 6-diazo-5-oxo-L-norleucine and acivicin in cell culture by glutaminase-asparaginase.
    Rosenfeld H; Roberts J
    Cancer Res; 1981 Apr; 41(4):1324-8. PubMed ID: 7214322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of plasma concentrations of uridine on pyrimidine biosynthesis in cultured L1210 cells.
    Karle JM; Anderson LW; Cysyk RL
    J Biol Chem; 1984 Jan; 259(1):67-72. PubMed ID: 6323418
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of N-(phosphonacetyl)-L-aspartate on 5-azacytidine metabolism in P388 and L1210 cells.
    Grant S; Rauscher F; Jakubowski A; Cadman E
    Cancer Res; 1981 Feb; 41(2):410-8. PubMed ID: 6160908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The glutamine analog acivicin as antipyrimidine. Studies on the interrelationship between pyrimidine and urea synthesis in liver.
    Pausch J; Rasenack J; Häussinger D; Holstege A; Gerok W
    Adv Enzyme Regul; 1985; 24():233-43. PubMed ID: 3835821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanism of resistance of variants of the Lewis lung carcinoma to N-(phosphonacetyl)-L-aspartic acid.
    Kensler TW; Mutter G; Hankerson JG; Reck LJ; Harley C; Han N; Ardalan B; Cysyk RL; Johnson RK; Jayaram HN; Cooney DA
    Cancer Res; 1981 Mar; 41(3):894-904. PubMed ID: 7459875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of acivicin and dichloroallyl lawsone upon pyrimidine biosynthesis in mouse L1210 leukemia cells.
    Kemp AJ; Lyons SD; Christopherson RI
    J Biol Chem; 1986 Nov; 261(32):14891-5. PubMed ID: 3771555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. N-(Phosphonacetyl)-L-aspartate inhibition of the enzyme complex of pyrimidine biosynthesis.
    Moore EC
    Biochem Pharmacol; 1982 Oct; 31(20):3313-6. PubMed ID: 7150357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanism of synergy between N-phosphonacetyl-L-aspartate and dipyridamole in a human ovarian carcinoma cell line.
    Chan TC; Howell SB
    Cancer Res; 1985 Aug; 45(8):3598-604. PubMed ID: 4016741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of deoxycytidine on the in vitro response of human leukemia cells to inhibitors of de novo pyrimidine biosynthesis.
    Bhalla K; Grant S
    Cancer Chemother Pharmacol; 1987; 19(3):226-32. PubMed ID: 3581416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Salvage of circulating pyrimidine nucleosides in the rat.
    Moyer JD; Oliver JT; Handschumacher RE
    Cancer Res; 1981 Aug; 41(8):3010-7. PubMed ID: 7248957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.